Oral GLP-1 agonist, Satiety Pathways, and Stem Cell tx for T1D
Update: 2025-06-27
1
1Description
Program notes:
0:40 Stem cells for type 1 diabetes
1:40 None had hypoglycemia afterwards
2:40 Autologous stem cells?
3:20 Oral GLP-1 agonist
4:20 Primary endpoint HbA1c reduction
5:20 Weight loss modest
6:20 Injectable GLP-1 plus an amylin analogue
7:20 Both those with diabetes and those without
8:20 No increased safety events
8:40 Mental health hospitalizations in adolescents
9:40 KID database
10:40 Females accounting for increase
11:40 67% of hospitalizations
12:57 End
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
